ZA984268B - Method and composition for administering taxanes orally to human patients - Google Patents

Method and composition for administering taxanes orally to human patients

Info

Publication number
ZA984268B
ZA984268B ZA984268A ZA984268A ZA984268B ZA 984268 B ZA984268 B ZA 984268B ZA 984268 A ZA984268 A ZA 984268A ZA 984268 A ZA984268 A ZA 984268A ZA 984268 B ZA984268 B ZA 984268B
Authority
ZA
South Africa
Prior art keywords
composition
human patients
administering taxanes
taxanes orally
orally
Prior art date
Application number
ZA984268A
Other languages
English (en)
Inventor
Samuel Broder
Kenneth L Duchin
Sami Selim
Original Assignee
Baker Norton Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baker Norton Pharma filed Critical Baker Norton Pharma
Publication of ZA984268B publication Critical patent/ZA984268B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA984268A 1997-05-27 1998-05-20 Method and composition for administering taxanes orally to human patients ZA984268B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US86351397A 1997-05-27 1997-05-27

Publications (1)

Publication Number Publication Date
ZA984268B true ZA984268B (en) 1999-06-23

Family

ID=25341241

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA984268A ZA984268B (en) 1997-05-27 1998-05-20 Method and composition for administering taxanes orally to human patients

Country Status (23)

Country Link
EP (1) EP0994706B1 (de)
JP (1) JP2002500667A (de)
KR (1) KR100615783B1 (de)
CN (2) CN1550231A (de)
AR (1) AR012731A1 (de)
AT (1) ATE308365T1 (de)
AU (1) AU7130098A (de)
BR (1) BR9809694A (de)
CA (1) CA2290446C (de)
CZ (1) CZ9904244A3 (de)
DE (1) DE69832173T2 (de)
DK (1) DK0994706T3 (de)
ES (1) ES2247690T3 (de)
HK (1) HK1026637A1 (de)
HU (1) HUP0003546A3 (de)
IL (2) IL132992A0 (de)
NO (1) NO995812L (de)
PL (1) PL337064A1 (de)
RU (1) RU2205005C2 (de)
SK (1) SK157599A3 (de)
UA (1) UA74767C2 (de)
WO (1) WO1998053811A1 (de)
ZA (1) ZA984268B (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6964946B1 (en) * 1995-10-26 2005-11-15 Baker Norton Pharmaceuticals, Inc. Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same
IL133585A0 (en) * 1997-06-20 2001-04-30 Baker Norton Pharma Soluble prodrugs of paclitaxel
GB9718903D0 (en) * 1997-09-05 1997-11-12 Glaxo Group Ltd Method,compositions and kits for increasing the oral bioavailability of pharmaceutical agents
DE60045114D1 (de) 1999-05-17 2010-11-25 Cancer Res Ventures Ltd Zubereitungen zur Erhöhung der Bioverfügbarkeit von oral verabreichten pharmazeutischen Verbindungen
CA2389583A1 (en) * 1999-10-27 2001-05-03 Baker Norton Pharmaceuticals, Inc. Method and compositions for administering taxanes orally to human patients
KR20020013174A (ko) * 2000-08-11 2002-02-20 민경윤 경구 흡수율이 낮은 약물의 흡수율을 증가시키기 위한경구용 조성물
US7115565B2 (en) 2001-01-18 2006-10-03 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
MXPA03006404A (es) * 2001-01-18 2004-12-02 Upjohn Co Composiciones quimioterapeuticas de microemulsion de paclitaxel con biodisponibilidad oral mejorada.
SI1372636T1 (sl) * 2001-02-28 2006-12-31 Bristol Myers Squibb Co Metronomsko odmerjanje taksanov za inhibiranje tumorske rasti
UY27185A1 (es) * 2001-02-28 2002-09-30 Bristol Myers Squibb Co Dosificación metronómica de taxanos
US7063977B2 (en) 2001-08-21 2006-06-20 Bristol-Myers Squibb Company Enzymatic resolution of t-butyl taxane derivatives
GB0523659D0 (en) * 2005-11-21 2005-12-28 Novartis Ag Organic compounds
KR20120050928A (ko) * 2009-06-02 2012-05-21 니칸 파마수티컬스, 엘엘씨 질병 치료용의 사람 포르밀 펩타이드 수용체의 길항제
EP4059497A1 (de) * 2021-03-17 2022-09-21 Dompé farmaceutici S.p.a. C5ar1 inhibitoren zur behandlung von hypersensitivitätsreaktionen auf taxane
CA3212816A1 (en) * 2021-03-17 2022-09-22 Dompe' Farmaceutici Spa C5ar1 inhibitors for treating hypersensitivity reactions to taxanes

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5411947A (en) * 1989-06-28 1995-05-02 Vestar, Inc. Method of converting a drug to an orally available form by covalently bonding a lipid to the drug
JPH06504772A (ja) * 1990-12-18 1994-06-02 ザ　ウエルカム　ファウンデーション　リミテッド 抗癌剤の薬効を増強し抗多剤耐性を有する薬剤
RU2119482C1 (ru) * 1991-01-11 1998-09-27 Лаборатуар Глаксо С.А. Производные акридина, способ получения, фармацевтическая композиция и способ лечения злокачественных опухолей
US5567592A (en) * 1994-02-02 1996-10-22 Regents Of The University Of California Screening method for the identification of bioenhancers through the inhibition of P-glycoprotein transport in the gut of a mammal
HU222496B1 (hu) * 1994-07-26 2003-07-28 Indena S.P.A. Félszintetikus taxánszármazékok, eljárás ezek előállítására, valamint ezeket tartalmazó gyógyászati készítmények
TW354293B (en) * 1995-06-06 1999-03-11 Bristol Myers Squibb Co Prodrugs of paclitaxel derivatives
US5916566A (en) * 1995-06-07 1999-06-29 Avmax, Inc. Use of benzoin gum to inhibit P-glycoprotein-mediated resistance of pharmaceutical compounds
US6245805B1 (en) * 1995-10-26 2001-06-12 Baker Norton Pharmaceuticals, Inc. Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
CA2221444A1 (en) * 1996-01-31 1997-08-07 Steven B. Hansel A method of making pharmaceutically active taxanes orally bioavailable
EP0814081A1 (de) * 1996-06-17 1997-12-29 Eli Lilly And Company Drogenresistente und multidrogenresistente Modulatoren
GB9718903D0 (en) * 1997-09-05 1997-11-12 Glaxo Group Ltd Method,compositions and kits for increasing the oral bioavailability of pharmaceutical agents
IL138767A0 (en) * 1998-04-01 2001-10-31 Rtp Pharma Inc Anticancer compositions

Also Published As

Publication number Publication date
KR20010013025A (ko) 2001-02-26
NO995812L (no) 2000-01-25
IL132992A (en) 2006-08-20
AR012731A1 (es) 2000-11-08
HUP0003546A2 (hu) 2002-11-28
CN1550231A (zh) 2004-12-01
CA2290446C (en) 2008-01-29
ES2247690T3 (es) 2006-03-01
BR9809694A (pt) 2000-10-03
RU2205005C2 (ru) 2003-05-27
WO1998053811A1 (en) 1998-12-03
HUP0003546A3 (en) 2002-12-28
CZ9904244A3 (cs) 2001-10-17
NO995812D0 (no) 1999-11-26
KR100615783B1 (ko) 2006-08-25
ATE308365T1 (de) 2005-11-15
DK0994706T3 (da) 2006-03-06
DE69832173T2 (de) 2006-08-03
CA2290446A1 (en) 1998-12-03
HK1026637A1 (en) 2000-12-22
PL337064A1 (en) 2000-07-31
UA74767C2 (en) 2006-02-15
EP0994706A1 (de) 2000-04-26
EP0994706B1 (de) 2005-11-02
CN1261275A (zh) 2000-07-26
JP2002500667A (ja) 2002-01-08
EP0994706A4 (de) 2001-05-16
IL132992A0 (en) 2001-03-19
DE69832173D1 (de) 2005-12-08
AU7130098A (en) 1998-12-30
SK157599A3 (en) 2002-10-08

Similar Documents

Publication Publication Date Title
PL341592A1 (en) Method of administering human aspb28 insulin
HUP0103357A3 (en) Halichondrin analogs and methods of their use and preparation
CY2007001I1 (el) Φαρμακευτικο σκευασμα για χρηση στη θεραπεια του διαβητη
HK1022835A1 (en) Pharmaceutical composition for treatment of diabetes
AU1805499A (en) Method and apparatus for delivery of therapeutic agents to the heart
HK1151462A1 (zh) 用於將物質給藥的植入物以及製備植入物的方法
HUP0000808A3 (en) Pharmaceutical composition of fenofibrate and method for preparing same
HUP0300836A3 (en) Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same
PL344246A1 (en) Novel pharmaceutical composition for use in emergency treatment and preparation method thereof
AUPO727097A0 (en) Method of treatment of hepatoma and pharmaceutical compositions for use therein
ZA984268B (en) Method and composition for administering taxanes orally to human patients
EP1129217A4 (de) Zusammensetzungen und verfahren zur krankheitsdiagnose und therapie
PL341230A1 (en) Solid dosage forms of ribavirin for oral administration and method of obtaining them
IL122405A (en) Methods for preparation of pharmaceutical composition for treatment of specific diseases using oils enriched in dha
IL149360A0 (en) Method and compositions for administering taxanes orally to human patients
EP1181022A4 (de) Medizinische zusammensetzungen und verfahren zu deren herstellung
EP1210075A4 (de) Zusammenstellungen und methoden zur veränderung des fettgehalts der haut
HUP9904317A3 (en) Use of 1-hydroxy-2-pyridones for producing pharmaceutical compositions suitable for the treatment of skin diseases
HUP0001526A3 (en) Use of nucleozides for producing pharmaceutical compositions for cytokine related treatments of disease and the pharmaceutical compositions
ZA964517B (en) Oral pharmaceutical composition of piperidinoalkanol compounds in solution form
EP1009433A4 (de) Therapeutische zusammensetzung und verfahren zur behandlung
AU784159C (en) Method and compositions for administering taxanes orally to human patients
HUP0203676A3 (en) Pharmaceutical composition and method for treatment of diabetes
HUP9801869A3 (en) Pharmaceutical composition for enhancing level of l-carnitin in human patients
GB9608927D0 (en) Method of treatment and pharmaceutical composition